CBLL
CeriBell, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$24.68
+0.46%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 102.0M | 89.1M | 65.4M | 45.2M | 25.9M |
| Cost of Revenue | 11.3M | 10.8M | 8.7M | 7.1M | 4.4M |
| Gross Profit | 90.6M | 78.3M | 56.8M | 38.2M | 21.5M |
| Operating Expenses | |||||
| R&D Expense | 23.0M | 19.1M | 13.6M | 9.0M | 7.2M |
| SG&A Expense | 137.7M | 117.5M | 82.9M | 59.2M | 50.3M |
| General & Admin Expense | 53.2M | 44.5M | 33.8M | 20.3M | 18.5M |
| Selling & Marketing Expense | 84.4M | 73.1M | 49.1M | 38.9M | 31.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 160.6M | 136.7M | 96.5M | 68.2M | 57.5M |
| Cost and Expenses | 171.9M | 147.5M | 105.2M | 75.3M | 61.9M |
| Operating Income (EBIT) | (70.0M) | (58.4M) | (39.7M) | (30.0M) | (36.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 1.8M | 1.9M | 2.0M | 2.1M | 1.6M |
| Net Interest Income | (1.8M) | (1.9M) | (2.0M) | (2.1M) | (1.6M) |
| Other Non-Op Income/Expense | 4.0M | 5.0M | (746.0K) | 588.0K | (1.1M) |
| Non-Operating Income (excl Interest) | (5.8M) | (6.9M) | (1.2M) | (2.7M) | (462.0K) |
| EBT (Pre-Tax Income) | (66.0M) | (53.4M) | (40.5M) | (29.5M) | (37.2M) |
| Income Tax Expense | — | — | — | 11.0K | 2.0K |
| Bottom Line | |||||
| Net Income | (66.0M) | (53.4M) | (40.5M) | (29.5M) | (37.2M) |
| Earnings from Cont. Ops | (66.0M) | (53.4M) | (40.5M) | (29.5M) | (37.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (66.0M) | (53.4M) | (40.5M) | (29.5M) | (37.2M) |
| Per Share | |||||
| Basic EPS | ($1.76) | ($1.46) | ($1.13) | ($1.26) | ($1.59) |
| Diluted EPS | ($1.76) | ($1.46) | ($1.13) | ($1.26) | ($1.59) |
| Revenue Per Share | $2.68 | $2.44 | $1.83 | $1.94 | $1.11 |
| Shares | |||||
| Basic Shares Outstanding | 38.0M | 36.5M | 35.9M | 23.3M | 23.3M |
| Diluted Shares Outstanding | 38.0M | 36.5M | 35.9M | 23.3M | 23.3M |
| Profitability Metrics | |||||
| EBITDA | (63.1M) | (50.2M) | (37.3M) | (26.5M) | (35.1M) |
| D&A | 1.1M | 1.3M | 1.1M | 847.0K | 497.0K |
| EBIT | (64.2M) | (51.5M) | (38.5M) | (27.4M) | (35.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026